ORIGINAL PAPER
Effects of lactoferrin on viral replication in B cell lines corresponding to various stages of B cell differentiation
1
Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Submission date: 2024-01-18
Final revision date: 2024-12-18
Acceptance date: 2025-04-28
Publication date: 2025-12-15
Corresponding author
Michał Zimecki
Michał Zimecki Hirszfeld Institute of Immunology and Experimental Therapy Rudolfa Weigla 12 53-114 Wrocław, Poland
Michał Zimecki Hirszfeld Institute of Immunology and Experimental Therapy Rudolfa Weigla 12 53-114 Wrocław, Poland
Medical Studies 2025;41(4):337-343
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Lactoferrin inhibits viral replication in many cell types.
Aim:
The aim of this study was to evaluate the protective effects of lactoferrin (LF) on susceptibility of B cell lines, representing different stages of differentiation, to viral infection.
Material and methods:
Native bovine LF (bLF) and recombinant mouse LF (rmLF) were applied. Mouse cell lines: WEHI-231 (immature B cells), A-20 (mature B cells), and 7TD1 (plasma cells) were used for infection with encephalomyocarditis virus (EMCV), herpes virus type 1 (HSV-1), and vesicular stomatitis virus (VSV).
Results:
A-20 cells were most sensitive to infection, WEHI-231 cells were less sensitive, while 7TD1 cells were most resistant to the infection. Both lactoferrins showed significant protective effects in WEHI-231 cells against EMCV, and in the case of A-20 cell line this effect was strongest. A potent antiviral effect of the lactoferrins was found in A-20 cells infected with HSV-1.
Conclusions:
The susceptibility of B-cell lines to viral infection, at various stage of cell differentiation, was differential. The protective effects of rmLF were higher in comparison to bLF.
Lactoferrin inhibits viral replication in many cell types.
Aim:
The aim of this study was to evaluate the protective effects of lactoferrin (LF) on susceptibility of B cell lines, representing different stages of differentiation, to viral infection.
Material and methods:
Native bovine LF (bLF) and recombinant mouse LF (rmLF) were applied. Mouse cell lines: WEHI-231 (immature B cells), A-20 (mature B cells), and 7TD1 (plasma cells) were used for infection with encephalomyocarditis virus (EMCV), herpes virus type 1 (HSV-1), and vesicular stomatitis virus (VSV).
Results:
A-20 cells were most sensitive to infection, WEHI-231 cells were less sensitive, while 7TD1 cells were most resistant to the infection. Both lactoferrins showed significant protective effects in WEHI-231 cells against EMCV, and in the case of A-20 cell line this effect was strongest. A potent antiviral effect of the lactoferrins was found in A-20 cells infected with HSV-1.
Conclusions:
The susceptibility of B-cell lines to viral infection, at various stage of cell differentiation, was differential. The protective effects of rmLF were higher in comparison to bLF.
REFERENCES (29)
1.
Rowe M, Fitzsimmons L, Bell AI. Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer. 2014; 33: 609-619.
2.
Márquez AC, Horwitz MS. The role of latently infected B cells in CNS autoimmunity. Front Immunol. 2015; 6: 544.
3.
Akula SM, Wang FZ, Vieira J, Chandran B. Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology. 2001; 282: 245-255.
4.
Marzi A, Möller P, Hanna SL, Harrer T, Eisemann J, Steinkasserer A, Becker S, Baribaud F, Pöhlmann S. Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis. 2007; 196: 237-246.
5.
Erlenhoefer C, Wurzer WJ, Löffler S, Schneider-Schaulies S, ter Meulen V, Schneider-Schaulies J. CD150 (SLAM) is a receptor for measles virus but is not involved in viral contact-mediated proliferation inhibition. J Virol. 2001; 75: 4499-44505.
6.
Yang L, Maruo S, Takada K. CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells. J Virol. 2000; 74: 10745-10751.
7.
Haan KM, Kwok WW, Longnecker R, Speck P. Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J Virol. 2000; 74: 2451-2454.
8.
Colin M, Mailly L, Rogée S, D’Halluin JC. Efficient species C HAdV infectivity in plasmocytic cell lines using a clathrin-independent lipid raft/caveola endocytic route. Mol Ther. 2005; 11: 224-236.
9.
Whitlock CA, Ziegler SF, Treiman LJ, Stafford JI, Witte ON. Differentiation of cloned populations of immature B cells after transformation with Abelson murine leukemia virus. Cell. 1983; 32: 903-911.
10.
Weissinger EM, Mischak H, Goodnight J, Davidson WF, Mushinski JF. Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas. Mol Cell Biol. 1993; 13: 2578-2585.
11.
Bouquet C, Melchers F. Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes. Eur J Immunol 2012; 42: 522-532.
12.
Kudo T, Tachibana T. Phenotype characteristics of human B cells studied by Epstein-Barr virus infection. II. C3 receptor switching during human B cell differentiation. Immunol Lett. 1984; 8: 343-348.
13.
Coleman CB, Nealy MS, Tibbetts SA. Immature and transitional B cells are latency reservoirs for a gammaherpesvirus. J Virol 2010; 84: 13045-13052.
14.
Sedger LM, Hou S, Osvath SR, Glaccum MB, Peschon JJ, van Rooijen N, Hyland L. Bone marrow B cell apoptosis during in vivo influenza virus infection requires TNF-alpha and lymphotoxin-alpha. J Immunol. 2002; 169: 6193-6201.
15.
Legrand D. Overview of lactoferrin as a natural immune modulator. J Pediatr. 2016; 173 Suppl: S10-S15.
16.
Redwan EM, Uversky VN, El-Fakharany EM, Al-Mehdar H. Potential lactoferrin activity against pathogenic viruses. C R Biologies. 2014; 337: 581-595.
17.
Välimaa H, Tenovuo J, Waris M, Hukkanen V. Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virol J. 2009; 6: 53.
18.
Di Biase AM, Pietrantoni A, Tinari A, Siciliano R, Valenti P, Antonini G, Seganti L, Superti F. Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J Med Virol. 2003; 69: 495-502.
19.
Zheng Y, Qin Z, Ye Q, Chen P, Wang Z, Yan Q, Luo Z, Liu X, Zhou Y, Xiong W, Ma J, Li G. Lactoferrin suppresses the Epstein-Barr virus-induced inflammatory response by interfering with pattern recognition of TLR2 and TLR9. Lab Invest. 2014; 94: 1188-1199.
20.
Zhou H, Zhu Y, Liu N, Zhang W, Han J. Effect of iron saturation of bovine lactoferrin on the inhibition of hepatitis B virus in vitro. Peer J. 2024; 12: e17302.
21.
Andreu S, Ripa I, Bello-Morales R, López-Guerrero JA. Liposomal lactoferrin exerts antiviral activity against HCoV-229E and SARS-CoV-2 pseudoviruses in vitro. Viruses. 2023; 15: 972.
22.
Hirai H, Adachi T, Tsubata T. Involvement of cell cycle progression in survival signaling through CD40 in the B-lymphocyte line WEHI-231. Cell Death Differ. 2004; 11: 261-269.
23.
Weaver EA, Chen CY, May SM, Barry ME, Barry MA. Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model. Hum Gene Ther. 2011; 22: 1095-1100.
24.
Van Snick J, Cayphas S, Vink A, Uyttenhove C, Coulie PG, Rubira MR, Simpson RJ. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. PNAS. 1986; 83: 9679-9683.
25.
Zaczyńska E, Artym J, Kocięba M, Burster T, Kruzel M, Paprocka M, Zimecki M. Antiviral resistance of splenocytes in aged mice. Pol J Microbiol. 2017; 66: 131-134.
26.
Jonsdottir HR, Zysset D, Lenz N, Siegrist D, Ruedin Y, Ryter S, Züst R, Geissmann Y, Ackermann-Gäumann R, Engler OB, Weber B. Virucidal activity of three standard chemical disinfectants against Ebola virus suspended in tripartite soil and whole blood. Sci Rep. 2023; 13: 15718.
27.
Tomczyk T, Orzechowska B. Vesicular stomatitis virus (VSV) as a vaccine vector for immunization against viral infections. Postep Hig Med Dosw. 2013; 67: 1345-1358.
28.
Chopra P, Yadavalli T, Palmieri F, Jongkees SAK, Unione L, Shukla D, Boons G-J. Synthetic heparanase inhibitors can prevent Herpes simplex viral spread. Angew Chem Int. 2023; 62: e202309838.
29.
Wróbel M, Małaczewska J, Kaczorek-Łukowska E. Antiviral effect of bovine lactoferrin against Enterovirus E. Molecules 2022; 27: 5569.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
